Initial diagnostic imaging technologies, including ultrasound, computed tomography (CT) and magnetic resonance imaging (MRI), provided several indications of abnormalities; however, PSMA PET/CT was instrumental in confirming the presence of primary prostate cancer and extensive metastases and assisting in precise staging and following appropriate therapeutic regimens for the disease. The gene discussed is FOLH1; the disease is prostate carcinoma.